A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
This study is looking into a new medicine called efgartigimod for adults who have a blood condition called primary immune thrombocytopenia (ITP). ITP causes low levels of platelets, which are important for blood clotting. The main goal is to find out how well efgartigimod works (its 'efficacy') and if it's safe to use. You'd first have a check-up period, then be randomly assigned to receive either the study drug (efgartigimod) or a dummy treatment (placebo) for up to 24 weeks. After this, everyone will receive efgartigimod for about two years, followed by a period where no study drug is given. The whole study could last up to 138 weeks.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is designed to learn more about a new treatment, efgartigimod, for adults living with primary immune thrombocytopenia, often just called ITP. ITP is a condition where your body's immune system mistakenly attacks and destroys its own platelets, which are tiny cells in your blood that help it clot. If you don't have enough platelets, you can bruise easily or bleed more than usual.
The researchers want to see if efgartigimod can help increase platelet counts and reduce bleeding in people with ITP. They also want to understand if the medicine is safe and doesn't cause too many side effects. Comparing it to a placebo (a treatment that looks like the real thing but has no active medicine) helps them truly see the effect of efgartigimod.
Participating could mean you receive a new treatment that might help your ITP, or you might receive a placebo at first. After a certain period, everyone in the study will get the active medicine. This type of research is really important because it helps doctors find better ways to manage conditions like ITP and improve the lives of people living with them.
النقاط الرئيسية
- This study is testing a new medicine for adults with ITP.
- It aims to see how well efgartigimod works and if it's safe.
- Participation involves receiving either the study drug or a placebo at first.
- Everyone on the study will get the active medicine eventually.
- The study involves regular clinic visits for IV treatments and check-ups.
- The total study duration could be up to 2.5 years.
من قد يكون مؤهلاً؟
To join this study, you need to be at least 18 years old. You must also have had primary ITP for more than a year and have a low platelet count. In the past, you should have tried at least one common ITP treatment (like steroids, IVIg, or other specific medicines) and it didn't work well enough.
There are also some reasons why you might not be able to join. For instance, if you have other serious health problems or a different type of ITP (not primary ITP), or if you have certain related conditions like another serious autoimmune disease or a current severe bleeding problem, you wouldn't be able to take part.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك لا يقل عن 18 عامًا؟
- Have you had primary ITP for more than one year?
- Do you currently have a low platelet count (less than 30)?
- Have you tried at least one previous ITP treatment (like steroids or IVIg) and it didn't work well enough?
- Have you had at least one platelet count of 50 or higher in response to a past ITP treatment (like prednisone, IVIg, etc.) in the last three years?
ماذا يتضمن المشاركة؟
If you decide to take part, you'll first have a screening period of up to two weeks to make sure the study is right for you. If you qualify, you'll be randomly assigned to one of two groups: either you'll receive efgartigimod, or you'll receive a placebo (a dummy medicine). You won't know which one you're getting, and neither will your study doctor, during this 'double-blind' period, which lasts up to 24 weeks.
After this initial phase, everyone will then receive efgartigimod for about 52 weeks. If you and your doctor agree, you might continue receiving efgartigimod for another 52 weeks. Throughout the study, you'll have regular visits to the clinic for check-ups, blood tests, and to receive your study medication, which will be given as an IV (into a vein). After all the treatment periods, there will be a follow-up period of about eight weeks where you won't be taking the study drug. The total time you'd be involved in the study could be up to 138 weeks (roughly 2.5 years).
المخاطر والفوائد المحتملة
Locations (94)
- Mayo Clinic Hospital Scottsdaleالرمز البريدي المؤكدفينيكس، الولايات المتحدة· التوظيف
- مركز نوريس الشامل للسرطان بجامعة جنوب كاليفورنياالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة· التوظيف
- مستشفى شارب التذكاريالرمز البريدي المؤكدأوشنسايد، الولايات المتحدة· التوظيف
- مستشفى جامعة كولورادوالرمز البريدي المؤكدأورورا، الولايات المتحدة· التوظيف
- كلية الطب بجامعة ييلالرمز البريدي المؤكدنيو هيفن، الولايات المتحدة· التوظيف
- Georgetown University Hospitalالرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة· التوظيف
- The University of Chicago Medicineالرمز البريدي المؤكدشيكاغو، الولايات المتحدة· التوظيف
- The University of Iowa Hospitals & Clinicsالرمز البريدي المؤكدمدينة آيوا، الولايات المتحدة· التوظيف
- Tulane Universityالرمز البريدي المؤكدنيو أورلينز، الولايات المتحدة· التوظيف
- Henry Ford Healthالرمز البريدي المؤكدديترويت، الولايات المتحدة· التوظيف
- جامعة مينيسوتاالرمز البريدي المؤكدمينيابوليس، الولايات المتحدة· التوظيف
- Regional Cancer Care Associates, LLC (RCCA)الرمز البريدي المؤكدLittle Silver, United States· التوظيف
أسئلة شائعة
What is primary immune thrombocytopenia (ITP)?
ITP is a blood disorder where your immune system attacks and destroys your own platelets, which are essential for blood clotting. This can lead to easy bruising or bleeding.
ما هو الإيفغارتيجمود؟
Efgartigimod is the new experimental medicine being tested in this study to see if it can help increase platelet counts in people with ITP.
ما هو "العلاج الوهمي"؟
A placebo is a treatment that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers understand the true effect of the active medication.
كيف سيتم إعطاء الدواء؟
The study medicine, efgartigimod (or the placebo), will be given as an intravenous (IV) infusion, meaning it will be delivered directly into a vein.
كم من الوقت سأكون في الدراسة؟
The study could last for up to 138 weeks, which is about two and a half years, including treatment and follow-up periods.
كيفية معرفة المزيد
Sabine Coppieters, MD
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.